Use Of A Response-Adapted Ruxolitinib-Containing Regimen For The Treatment Of Hemophagocytic Lymphohistiocytosis

Condition:   Hemophagocytic Lymphohistiocytosis Interventions:   Drug: Ruxolitinib;   Drug: Dexamethasone;   Drug: Etoposide Sponsors:   St. Jude Children's Research Hospital;   Incyte Corporation;   North American Consortium for Histiocytosis Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials